- Abbott to commercialize several biosimilar molecules in key
emerging markets in Latin America,
Southeast Asia, the Middle East and Africa
- Spain-based global biotech
leader mAbxience Holdings S.L. to develop, manufacture and supply
the biosimilar molecules
- First molecules expected to launch as early as 2025, offering
new treatment options that leverage the latest in scientific
breakthroughs for people in emerging markets
ABBOTT PARK, Ill., Sept. 20, 2023
/PRNewswire/ -- Abbott (NYSE: ABT) announced today an agreement
with Spain-based global biotech
leader mAbxience Holdings S.L. to commercialize several biosimilars
focusing on oncology, women's health and respiratory diseases in
emerging markets. The first molecules are expected to launch in
2025, while others are subject to the completion of clinical
development and registration. Abbott will register and
commercialize the biosimilars in key emerging countries in
Latin America, Southeast Asia, the Middle East and Africa, leveraging the company's broad
in-country footprint to make these cutting-edge medicines available
to more people in emerging countries.
mAbxience, with majority ownership from Fresenius Kabi and
partial ownership from Insud Pharma, will manufacture the
biosimilars in one of its two state-of-the art and Good
Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be
responsible for achieving the clinical milestones for some of the
molecules still undergoing development.
This collaboration broadens Abbott's medicines offering in
emerging countries and expands an existing agreement with
mAbxience, initiated in Latin
America in 2018. Through this agreement, Abbott provided
access to treatment options for two cutting-edge oncology
biosimilars in various countries including Colombia, Chile and Peru, and in Central
America.
"The expanded collaboration with mAbxience will complement our
existing branded generic medicines portfolio with state-of-the-art
biosimilars," said Daniel Salvadori,
executive vice president and group president, Established
Pharmaceuticals and Nutritional Products, Abbott. "With our large
footprint in emerging countries and our commitment to put access
and affordability at the center of what we do, this strategic
collaboration will help more people in more places have access to
affordable biosimilar medicines."
With worldwide population aging and changing lifestyles,
non-communicable diseases such as cancer are on the
rise1. For people in emerging countries, access to care
is often not optimal due to physical challenges in accessing a
doctor – especially in rural areas – and limitations in standards
of care, as the latest innovations may not be available. Lacking
access to treatment options and care is one of the reasons why
people in emerging countries are much more likely to die from these
diseases than people in wealthier countries.2 More than
three-quarters of all deaths worldwide from chronic diseases happen
in emerging countries. In Brazil
and Mexico, up to 40 percent of
cancer patients who may benefit from biologics do not receive the
therapy they need.3
"Collaborating with Abbott's medicines business is a key
strategic step to help bring our biosimilars into the hands of more
people who need them," said Emmanuelle
Lepine, chief executive officer, mAbxience. "Abbott shares a
common vision of making high-quality medicines available so that
healthcare systems can have cost-effective treatment options, with
an opportunity for more people around the world to get healthier.
This new agreement supports our strategy of becoming a leading
global player within the biosimilar space."
This collaboration will commercialize biosimilars in select key
emerging markets. It will help introduce life-saving treatments in
key oncology, women's health and respiratory diseases for the first
time in some countries, at a fraction of the cost of originator
biologics, making it more accessible and affordable for healthcare
systems in these countries.
About Abbott:
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn
at www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
About mAbxience:
mAbxience is a Spanish-based company
specializing in the development, production, and commercialization
of biopharmaceuticals. In August
2022, Fresenius Kabi and Insud Pharma entered into an
agreement whereby Fresenius Kabi acquired a majority stake of
mAbxience, making it a global, vertically integrated fully-fledged
biotechnology company. For more insights into mAbxience and
the company's biosimilars business and contract development and
manufacturing organization (CDMO) business, please
visit https://www.mabxience.com/ or connect on LinkedIn.
1 Pan American Health Organization. (2023,
June 30). The rising burden of
non-communicable diseases in the Americas and the impact of
population aging: a secondary analysis of available data - PAHO/WHO
| Pan American Health Organization. www.paho.org.
https://www.paho.org/en/node/91897
2 WHO. Non communicable diseases. 2022. Available from:
https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
3 IQVIA Institute for Human Data Science. 2020. The
Impact of Biosimilar Competition in Europe. Available from:
https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe
View original
content:https://www.prnewswire.co.uk/news-releases/abbott-broadens-access-to-cutting-edge-biosimilars-in-key-emerging-markets-301932956.html